Differentially expressed genes associated with TMPRSS2-ERG molecular subtype of prostate cancer

Poster (download) Anastasiya Andreevna Kobelyatskaya1, Elena Anatolevna Pudova2, George Sergeevich Krasnov3, Anna Victorovna Kudryavtseva4, Kirill Mikhailovich Nyushko5, Boris Yakovlevich Alekseev61EIMB RAS, kaa.chel@mail.ru2EIMB RAS, pudova_elena@inbox.ru3EIMB RAS, gskrasnov@mail.ru4EIMB RAS, rhizamoeba@mail.ru5FSBI NMRRC, kirandja@yandex.ru6FSBI NMRRC, mnioi@mail.ru Prostate cancer (PC) is one of the most common and socially significant oncological diseases in men. This study examined the transcriptome profile of the most common molecular genetic subtype of prostate cancer, TMPRSS2-ERG. As a result of bioinformatics analysis conducted on the basis of The Cancer Genome Atlas project data, 115 differentially expressed genes were identified for this study group, and in particular, the most over-expressing genes were identified: ALOX15, CACNA1D, EML6, HLA-DMB, NKAIN1, OGDHL, PLA1A, SYT13. Enrichment pathways analysis showed that these genes are participants in important oncologically significant pathways, which emphasizes the association of this molecular subtype with an unfavorable prognosis for prostate cancer.

Read More

Intermediate and high-risk prostate cancer methylation analysis

Poster (download) Elena Pudova11EIMB RAS, pudova_elena@inbox.ru Prostate cancer is one of the most important socially significant oncological diseases in men. To select an effective approach to therapy, prostate cancer is stratified into appropriate risk groups based on criteria such as TNM status, Gleason score and the level of prostate-specific antigen (PSA). However, to optimize therapy, additional informative markers are necessary, and the aim of this study is to search for these markers at the level of genome methylation. This work included methylation data of prostate cancer from The Cancer Genome Atlas project. The cohort involved patients with high (23 cases) and intermediate (103 cases) risk. As a result, 1,056 differentially methylated CpG sites were found between high and medium risk groups. CpG most interested sites: cg17687367 (chr13: 79936801), cg26874611 (chr5: 168147884), cg06989693 (chr5: 41409252), cg02226810 (chr6: 1605117), cg07736716 (regulation regions: 85): 85 to 91 (85): 85 858: 858: 858: 85: 86: 85: 86: 85: 86: 85: 86: 85: 86: 85: 85.

Read More